Tender Details

Country: Czech Republic
Summary: Medicinal Product for Autologous Cell Therapy - Brexukabtagen Autoleucel - 2025
CZT Ref No: 131846769
Deadline: 13 Jan 2026
Financier: Self Financed
Purchaser Ownership: Government
Tender Value: CZK 146172000
Notice Type: Tender
Document Ref. No.: 821311-2025
Purchaser's Detail:
Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
Login to see details
Description:
The subject of the public contract is the supply of a medicinal product intended for the therapy of malignant blood diseases in the total expected volume of 16 individual doses of the medicinal product. The preparation is intended for the provision of health care at the FN medical workplace Pilsen. Deliveries of the subject of performance will be carried out on the basis of the results of the completed procurement procedure for a period of four years from the signing of the purchase contract. cytostatic drug for CAR-T therapy - brexukabtagen autoleucel The subject of the public contract is the supply of medicinal products intended for the therapy of malignant blood diseases in the total expected volume of 16 individual doses of the medicinal product. The preparation is intended for the provision of health care at the medical workplace of the FN Plzeň. Deliveries of the subject of performance will be made on based on the results of the completed procurement procedure for a period of four years from the signing of the purchase contract. Cytostatic agent for CAR-T therapy (brexukabtagen autoleucel) - infusion bag containing a cell dispersion of 0.4 - 2x10^8 viable anti-CD19 CAR-positive T-lymphocytes. The expected annual volume is 4 infusion bags containing an individually determined amount of the active ingredient, ATC L01XL06. Doc Title: Medicinal product for autologous cell therapy - brexukabtagen autoleucel - 2025 Contract Type: supplies
Documents:

If you are registered member, kindly login to view full details of this tender notice:

Medicinal Product for Autologous Cell Therapy - Brexukabtagen Autoleucel - 2025 - Czech Republic Tender

The UNIVERSITY HOSPITAL PILSEN, a Government sector organization in Czech Republic, has announced a new tender for Medicinal Product for Autologous Cell Therapy - Brexukabtagen Autoleucel - 2025. This tender is published on CzechRepublicTenders under CZT Ref No: 131846769 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2026-01-13.

The estimated tender value is CZK 146172000, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.